Related by context. All words. (Click for frequent words.) 81 Orphan Drug Status 78 Orphan Drug status 78 Fast Track designation 78 Fast Track Status 74 Orphan Designation 74 Orphan Drug designation 73 Orphan Status 72 Orphan Medicinal Product 72 Orphan Drug Designation 71 orphan designation 69 Granted Orphan Drug 69 Severe VOD 69 Receives Orphan Drug Designation 69 Fast Track designations 68 Orphan Drug designations 68 Supplemental Biologics License Application 68 FDA Accepts 68 FDA Orphan Drug 67 Phase IIb Trial 67 Priority Review 67 NDA Submission 67 Phase 2b Clinical Trial 67 Phase III Clinical Trial 67 Expanded Indication 67 Meets Primary Endpoint 66 Accelerated Approval 66 orphan medicinal product 66 Pivotal Trial 66 Vandetanib 66 Investigational Device Exemption 66 OMP designation 66 Files IND 65 Patient Enrollment 65 Patent Covering 65 Fibrillex TM 65 Orphan Drug 65 Product Designation 65 Trobalt 65 Investigational Treatment 65 FDA Approvable Letter 65 Orphan designation 64 Drug Candidate 64 Marketing Authorization Application 64 Receives Orphan Drug 64 Pivotal Phase III 64 Soliris TM eculizumab 64 Phase III Trial 64 Positive Opinion 64 Demonstrates Significant 64 Romiplostim 64 Completes Patient Enrollment 64 Cellegesic 64 Initiate Clinical Trial 64 Dupuytren Contracture 64 Adjuvant Treatment 64 FOLOTYN ® 64 Advanced Melanoma 63 IND Filing 63 PNP inhibitor 63 Application MAA 63 Metastatic Colorectal Cancer 63 Panzem R 63 supplemental Biologics License Application 63 Patients Treated With 63 Personalized Immunotherapy 63 SBIR Grant 63 VIVITROL ® 63 Metastatic Melanoma 63 Phase IIb Clinical Trial 63 Taro Receives 63 Mylan Receives Approval 63 Oral Calcitonin 63 TNF Tumor Necrosis Factor 63 TEMODAL 63 Civacir 63 Psoriasis Drug 63 R lenalidomide 63 granted Ortec 63 Marketing Authorisation 63 ThermoDox R 63 Acute Attacks 63 investigational humanized monoclonal antibody 63 Submits NDA 63 Cutaneous T 63 Crofelemer budesonide foam 63 MyVax R 63 EVIZON TM 63 Receives Positive Opinion 63 Vitrasert R 63 GTC recombinant form 63 Troxatyl 63 Marketing Authorisation Application 63 Pazopanib 63 Ranolazine 63 Pivotal Study 63 HepaGam B 63 vitreoretinal disorders 63 FDA Clearance 63 Serostim ® 63 IND Application 62 drug ISA# 62 Initiates Phase II 62 Completes Enrollment 62 OMAPRO ™ 62 TORISEL 62 pseudobulbar affect PBA 62 Generic Version 62 Files Investigational 62 receptor tyrosine kinase inhibitor 62 pediatric Crohn disease 62 Phase 1b Clinical Trial 62 Phase 2b Trial 62 Confirmatory Phase 62 Marketing Authorization 62 JAK Inhibitor 62 Achieves Primary Endpoint 62 Pafuramidine 62 refractory chronic lymphocytic 62 PROMACTA 62 Pralatrexate 62 Ofatumumab 62 SomatoKine 62 Severe Sepsis 62 ThermoDox ® 62 Pivotal Phase 62 Everolimus 62 Investigational Compound 62 REVLIMID R 62 Improves Survival 62 IL# PE#QQR 62 TORISEL TM 62 Therapy Evaluation 62 Pegloticase 62 ADVEXIN p# therapy 62 Dyloject TM 62 Initiates Phase III 62 Somatuline Depot 62 acetonide FA 62 sapropterin dihydrochloride 62 Clinical Trial Evaluating 62 Methylnaltrexone 62 methylnaltrexone 62 StaphVAX R 61 vapreotide acetate 61 FDA Approvals 61 Milestone Payment 61 Pixantrone 61 Diabetic Macular Edema 61 oral prodrug 61 lucinactant 61 dasatinib Sprycel ® 61 #D#C# 61 Pirfenidone 61 Glufosfamide 61 MAGE A3 ASCI 61 Monotherapy 61 Grants Orphan Drug 61 Receives Fast Track 61 orphan drug 61 Kit CD# positive 61 severe oral mucositis 61 Alair System 61 Receives Approvable Letter 61 k Clearance 61 miconazole Lauriad R 61 PEGylated Fab fragment 61 Humanitarian Device Exemption 61 Nabi HB Intravenous 61 Initiates Enrollment 61 Entereg R 61 Biologic License Application BLA 61 JAK2 Inhibitor 61 Expedited Review 61 Presents Preclinical Data 61 cutaneous T 61 Evoltra ® 61 acyclovir Lauriad R 61 PROVENGE ® 61 Tyrosine Kinase Inhibitor 61 Efficacy Trial 61 Phase 2a Trial 61 Soft Tissue Sarcoma 61 Pivotal Clinical Trial 61 Drug Eluting Stent System 61 Angiox ® 61 liver resection surgeries 61 PrevOnco ™ 61 Icatibant 61 Aviptadil 61 Bafetinib 61 PANVAC VF 61 Prolongs Survival 61 cinacalcet HCl 61 Voraxaze 61 chronic idiopathic thrombocytopenic purpura 61 Initiates Clinical Trial 61 Complete Response 61 Application BLA 61 PDUFA Date 61 Ridaforolimus 61 generation purine nucleoside 61 Maribavir 61 systemic immunosuppressive drugs 61 Resten NG 61 selective A2A adenosine receptor 61 BLA filing 61 Submits Biologics License Application 61 Receives Marketing Authorization 61 Torisel 61 Phase III Trials 61 FDA Approval 61 GTC recombinant human 61 investigational monoclonal antibody 61 Liprotamase 61 VISICOL R 61 Iluvien ® 61 Lambert Eaton Myasthenic 61 Efficacy Results 61 Preclinical Data 61 Kuvan R 61 Granulocyte Colony Stimulating Factor 61 Milestone Payment From 61 oropharyngeal candidiasis OPC 61 Cimzia TM 61 Noxafil 60 SYCREST 60 Improves Outcomes 60 GATTEX TM 60 SPRYCEL ® 60 SNT MC# 60 Adjuvant Therapy 60 Aliskiren 60 CryoSeal FS System 60 Advanced Renal Cell 60 Bezielle 60 Premarket Approval 60 Resubmission 60 Alemtuzumab 60 rilonacept 60 LUCASSIN 60 Cx# [002] 60 Intravenous CP 60 Submits Supplemental 60 Replacement Therapy 60 Investigational Agent 60 Lubiprostone 60 CINTREDEKIN BESUDOTOX 60 Actemra tocilizumab 60 Glatiramer Acetate 60 Fabry Disease 60 chronic eosinophilic leukemia 60 Microplasmin 60 novel oral anticoagulant 60 Irinotecan 60 Bendamustine 60 ENTEREG ® 60 Cinryze TM 60 Tezampanel 60 Bazedoxifene 60 LUVENIQ 60 Phase 2a Clinical Trial 60 Lenalidomide 60 severe gastroparesis 60 Prodarsan 60 Friedreich Ataxia FRDA 60 Arimoclomol 60 II Clinical Trial 60 sorafenib tablets 60 Taliglucerase alfa 60 Initiate Phase 60 Milestone Payments 60 Systemic Delivery 60 Receives Milestone Payment 60 Survival Benefit 60 Etravirine 60 ISTODAX ® 60 Besivance 60 MAA submission 60 Successfully Completes Phase 60 IMA# 60 Receives CE Marking 60 orally administered inhibitor 60 SUPPRELIN R LA 60 PGL# 60 Fludara ® 60 Hematological Malignancies 60 ONGLYZA ™ 60 SUTENT 60 Angiox R 60 Interferon Beta 60 ATryn R 60 Recommends Approval 60 Peginterferon alfa 2b 60 Myelodysplastic Syndromes 60 Dose Escalation 60 Oral Cladribine 60 Vitrasert ® 60 oral nucleoside analogue 60 sBLA 60 NPC 1C 60 Pulmonary Arterial Hypertension 60 Romidepsin 60 Colorectal Cancer Patients 60 Syndrome LEMS 60 Disease Progression 60 Hsp# Inhibitor 60 Luveniq 60 Announces Tentative Approval 60 Conditional Approval 60 Etanercept 60 hypereosinophilic syndrome 60 FDA APPROVES 60 ZACTIMA 60 Approvable Letter 60 Patient Enrolment 60 TRANSDUR ™ 60 Project QTDP 60 ZOLINZA 60 Diabetic Ulcers 60 Epratuzumab 60 AVASTIN 60 SinuNase TM 60 HDAC Inhibitor 60 Zenpep 60 Study Evaluating 60 UPLYSO 60 Archexin 60 Aflibercept 60 Acute Ischemic Stroke 60 DORIBAX 60 PrevOnco 60 Oral Mucositis 60 First Patient Treated 60 Testosterone Gel 60 thalidomide Thalomid 60 Dacogen injection 60 Lenocta TM 60 methylnaltrexone bromide 60 MEK Inhibitor 60 Xyfid TM 60 Submits Response 60 Kepivance 60 histamine dihydrochloride 60 Previously Treated 60 Immunotherapeutic 60 granted orphan 60 Tigecycline 60 PROMACTA ® 59 Dapagliflozin 59 Initiates Clinical 59 Pradefovir 59 gastrointestinal disorders characterized 59 Trial Evaluating 59 eosinophilic asthma 59 autologous cellular immunotherapy 59 Genasense R 59 RNAi Therapeutic 59 ADP receptor antagonist 59 ELADUR ™ 59 Zorbtive TM 59 BEMA Granisetron 59 Phase #b/#a clinical 59 Gleevec imatinib mesylate 59 Prodarsan R 59 SANVAR 59 Adjunctive Therapy 59 PRN FDA Approves 59 Degarelix 59 Horizant ™ 59 Clofarabine 59 Complicated Skin 59 Bevacizumab 59 Is Well Tolerated 59 human C1 inhibitor 59 Boceprevir 59 registrational trial 59 Dose Ranging Study 59 Esbriet ® 59 Treatment Regimen 59 R adalimumab 59 BCG refractory carcinoma 59 ATryn ® 59 Surfaxin LS 59 erlotinib Tarceva ® 59 targeted radiotherapeutic 59 Protease Inhibitor 59 Mepact 59 Bayer Nexavar 59 Tesamorelin 59 Investigational Device Exemption IDE 59 Esbriet pirfenidone 59 Sapacitabine 59 Well Tolerated 59 Genasense ® 59 Anthim 59 Submits Investigational 59 Pneumococcal Vaccine 59 First Patient Dosed 59 Vimpat R 59 R sorafenib tablets 59 Combination Treatment 59 LEUKINE 59 steroid refractory GvHD 59 Bayer Onyx 59 REVLIMID lenalidomide 59 First Patient Enrolled 59 Combination Therapy 59 Ecallantide 59 Valortim TM 59 BENLYSTA ® 59 investigational pharmacologically unique 59 Begins Dosing 59 Melphalan 59 octreotide implant 59 Clinical Trial Results 59 Saforis 59 Spiegelmer ® 59 KIACTA ™ 59 LymphoStat B belimumab 59 Kuvan TM sapropterin 59 Hepatitis C Virus HCV 59 Alvesco R 59 Amrubicin 59 BRILINTA 59 ISTODAX 59 Neuroendocrine Tumors 59 Recombinant Human 59 Multiple Myeloma Patients 59 5 lipoxygenase inhibitor 59 Investigational Drug 59 personalized cellular immunotherapy 59 Onco TCS 59 Cholesterol Lowering Drug 59 ® decitabine 59 Firazyr 59 Nimotuzumab 59 Teva Provides Update 59 Marketing Authorization Application MAA 59 VitiGam TM 59 VALSTAR 59 CYT# potent vascular disrupting 59 PDE4 inhibitor 59 Androxal ® 59 Initiates Phase 59 Orally administered 59 Evoltra 59 formerly LymphoStat B 59 unresectable recurrent 59 Tolvaptan 59 Biological License Application 59 CHMP recommendation 59 Tarceva TM 59 Rhucin ® recombinant 59 IONSYS TM 59 lintuzumab SGN 59 Androgen Deprivation Therapy 59 Albuferon TM 59 Prestara TM 59 Malignant Melanoma 59 Bioral Amphotericin B 59 ANDA Filing 59 Initiates Phase 2b 59 Opterone R 59 molecular imaging radiopharmaceutical 59 Raptiva ® 59 Prostate Cancer Vaccine 59 DC Bead 59 Eltrombopag 59 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 59 Azedra 59 Lenocta 59 Development OOPD 59 MGd 59 PLK1 SNALP 59 Presents Positive 59 rasagiline tablets 59 VIBATIV 59 sunitinib Sutent 59 docetaxel Taxotere ® 59 Xcytrin R 59 PEGylated anti 59 ixabepilone 59 opioid induced constipation OIC 59 Infected Patients 59 Sprycel dasatinib 59 investigational oral inhibitor 59 Arzerra ofatumumab 59 Phase 2b Study 59 Li Fraumeni Syndrome 59 Simulect 59 pralatrexate injection folate analogue 59 Prestara 59 Refractory Peripheral T 59 OMNARIS HFA 59 Oral Fingolimod 59 Reports Preclinical Data 59 Manja Bouman CEO 59 Febuxostat 59 Government Qualifying Therapeutic 59 Oral Spray 58 MEND CABG II 58 Single Dose 58 Patients Treated 58 Combination REOLYSIN R 58 RNAi Therapeutics 58 Clevudine 58 TroVax ® 58 Denufosol 58 granted Orphan Drug 58 Exclusive License 58 Ceflatonin 58 Neoadjuvant 58 NEUMUNE 58 Elagolix 58 Gamunex C 58 herpetic keratitis 58 ACUROX 58 HP Acthar Gel repository 58 LymphoStat B TM 58 Zingo TM 58 alfa 2a 58 Gout Drug 58 TRANSDUR ® 58 Therapeutic Vaccine 58 Phase III Pivotal Trial 58 Fortical R 58 5 HT3 antagonist 58 Stem Cell Treatment 58 Cethromycin 58 PROGENSA R 58 Pfizer Sutent 58 Fondaparinux 58 Nexavar ® 58 ENTB 58 candidate TNFerade biologic 58 Vascugel 58 Anturol TM 58 Initiate Phase III 58 Allovectin 7 58 Intravenous Formulation 58 Evoltra TM 58 Chronic Lymphocytic Leukemia CLL 58 Contrave NDA 58 liposomal formulation 58 Golimumab 58 Phase IIa Clinical Trial 58 IgG1 monoclonal antibody 58 EvaMist TM 58 Present Preclinical Data 58 oxypurinol 58 Ixempra 58 interferon gamma 1b 58 Awarded Qualifying Therapeutic 58 registrational studies 58 Prosaptide 58 Somatuline Autogel 58 aldehyde dehydrogenase ALDH2 deficiency 58 Oral BDP 58 candidate deforolimus 58 Rilonacept 58 novel histone deacetylase 58 Shows Efficacy 58 targeted antifolate 58 Biologics License Application 58 SURFAXIN 58 PREOS R 58 Impax ANDA 58 Improve Survival 58 myelodysplastic myeloproliferative diseases 58 Octreolin 58 lymphoid malignancies 58 Uvidem 58 % uracil topical 58 TKB# 58 NEBIDO R 58 Bucindolol 58 Hedgehog Pathway Inhibitor 58 oral ridaforolimus 58 Mimpara 58 Argatroban 58 HepeX B TM 58 drug pipeline TAFA# 58 Trovax 58 ARIKACE ™ 58 alvimopan 58 HoFH 58 exocrine pancreatic insufficiency EPI 58 AA amyloidosis 58 Amigal TM 58 Patent Broadly Covering 58 Cimzia certolizumab pegol 58 pediatric exclusivity 58 induced macular edema 58 subsidiaries visit http:/www.apricusbio.com 58 Ceflatonin ® 58 Shows Promise Against 58 Oracea ® 58 hereditary antithrombin deficiency 58 Regenerative Cells 58 Adjuvant Chemotherapy 58 mTOR kinase 58 BiovaxID TM 58 Diabetic Neuropathy 58 Preotact 58 Gene Therapy Trial 58 Yondelis ® 58 small molecule thrombopoietin 58 Ciclesonide 58 CIP TRAMADOL ER 58 GW# [003] 58 Inhaled Insulin 58 candidates Azedra TM 58 Hormone Refractory Prostate Cancer 58 Mouse Model 58 IDE Investigational Device Exemption 58 Perifosine 58 Levoleucovorin 58 Aloxi R 58 dextromethorphan quinidine 58 Demonstrates Efficacy 58 Augment TM 58 lenalidomide Revlimid R 58 Zenvia ™ 58 Lung Cancer Drug 58 Radiofrequency Ablation RFA 58 Bosutinib 58 terlipressin 58 Newly Diagnosed Multiple Myeloma 58 post menopausal osteoporosis 58 ONCASPAR 58 ALN TTR 58 pancreatic insufficiency 58 Entereg TM 58 OHR/AVR# 58 motexafin gadolinium Injection 58 abatacept Orencia 58 XIAFLEX ™ 58 ACOMPLIA R 58 mertansine 58 Biologic License Application 58 prokinetic agent 58 R Saizen R 58 Tanespimycin 58 Sanvar R 58 Act PDUFA date 58 systemic fungal infections 58 aerosolized AAT 58 Loxapine 58 advanced carcinoid 58 imatinib Gleevec ® 58 Liver Toxicity 58 LHRH antagonist 58 phase IIb clinical 58 Nasdaq VNDA 58 Epilepsy Drug 58 Plicera 58 Brentuximab Vedotin SGN 58 BCR ABL inhibitor 58 Combo Therapy 58 ALN PCS 58 mu opioid receptor antagonist 58 Demonstrates Potential 58 Cinacalcet HCl 58 sublingual tablets 58 Initiate Phase II 58 Vidaza azacitidine 58 Rifaximin 58 Advanced Prostate Cancer 58 FIRAZYR 58 Tasimelteon 58 treat chronic sinusitis 58 severe hypercholesterolemia 58 MPS VI 58 markets HP Acthar 58 Darunavir 58 TO AVOID PREGNANCY WHILE 58 Phase IIB 58 Hiberix 58 chronic thromboembolic pulmonary 58 Factor VIIa 58 TYKERB 58 Retacrit 58 Aurora Kinase 58 Belimumab 58 Generic Version Of 58 Node Positive 58 Receives Complete Response 58 TELINTRA 58 TREANDA 58 HepeX B 58 granted Orphan Designation 58 Loramyc R 58 XYOTAX TM 58 cell lymphoma CTCL 58 Dasatinib 58 Antibody Drug Conjugate 58 Solzira TM 58 injectable formulation 58 reslizumab 58 Nasdaq Delisting Notification 58 catheter occlusion 58 Zebinix R 58 non metastatic osteosarcoma 58 HCV Protease Inhibitor 58 Qualified Therapeutic Discovery 58 ACUROX ® 58 TYZEKA 58 Novel Oral 58 POSIDUR TM ELADUR TM 58 Eculizumab 58 Allovectin 7 r 58 Vicinium TM 58 ALN HPN 58 BYETTA ® 57 Fidaxomicin 57 targeting CD# 57 Enzyme Replacement Therapy 57 Carbidopa 57 diarrhea predominant irritable 57 Aurexis 57 Onconase 57 NOXAFIL 57 Cimzia ® certolizumab pegol 57 sunitinib malate 57 Cetrorelix 57 relapsing multiple sclerosis 57 Immunosuppressant 57 FRDA 57 Omalizumab 57 Wyeth Torisel 57 adalimumab Humira 57 acute peripheral arterial 57 Zarnestra 57 Sagent Pharmaceuticals Announces 57 Xanafide 57 oropharyngeal candidiasis 57 Carboplatin Paclitaxel 57 GRAS Status 57 Raptiva R 57 Annamycin 57 cinacalcet 57 Eniluracil 57 Schizophrenia Drug 57 Pemetrexed 57 Torisel temsirolimus 57 Improved Survival 57 ABILIFY R 57 Antitumor Activity 57 Soliris eculizumab 57 Cinryze ™ 57 Prospective Randomized 57 ATryn ® GTC recombinant 57 REVLIMID ® 57 RhuDex 57 IONSYS 57 Pharmacokinetics PK 57 Extended Release Capsules 57 anticancer compound 57 FDA Okays 57 Ceflatonin R 57 Submits Application 57 Telavancin 57 Extended Release 57 sorafenib Nexavar 57 ONSOLIS 57 mTOR inhibitor 57 IAP inhibitor 57 Previously Untreated 57 Blood Pressure Drug 57 Neurodex 57 Protexia ® 57 R bendamustine hydrochloride 57 lymphoma CTCL 57 dependent kinase inhibitor 57 Pruvel 57 omega interferon 57 ferumoxytol Injection 57 FOR FURTHER INFORMATION ABOUT 57 Cloretazine ® 57 EOquin 57 Spectrum Pharmaceuticals Announces 57 Advagraf 57 Generx TM 57 Sumatriptan Succinate 57 ZEGERID Chewable Tablets 57 Angiox 57 Velaglucerase Alfa 57 Long Term Efficacy 57 SUTENT ® 57 Silodosin 57 beta 1a 57 Topical Treatment 57 LibiGel ® 57 Tacrolimus 57 Bioral ® 57 Clolar 57 TNF Blockers 57 Linjeta TM 57 Prochymal TM 57 ZEFTERA TM Zevtera TM 57 Transdermal Patch 57 huC# DM4 57 Interferon Alpha 57 IND Investigational New 57 Antithrombin 57 metastatic hormone refractory 57 C1 Inhibitor 57 mesylate tablets approved 57 BioSTAR R 57 subependymal giant cell 57 ALVESCO R 57 Initiates Clinical Trials 57 Pivotal Trials 57 Ambrisentan 57 Perflubutane Polymer Microspheres 57 Drug Shows Promise 57 novel emulsion formulation 57 Chronic Hepatitis C 57 Ganite ® 57 XL# anticancer compounds 57 Critical Limb Ischemia 57 ARIXTRA R 57 microRNA Therapeutics 57 Clinical Study Shows 57 Wafer polifeprosan 57 corticotropin injection 57 Treatment IND 57 Aryplase 57 investigational antiplatelet agent 57 Myoblast 57 RANK Ligand inhibitor 57 Toremifene 57 Renal Cell Carcinoma 57 ONGLYZA TM 57 Treatment Naïve Patients 57 phase IIb trial 57 Emezine 57 candidate XP# 57 investigational antibiotic 57 Azacitidine 57 radiation sensitizer 57 prGCD 57 indiplon capsules 57 dirucotide MBP# 57 topical gel formulation 57 Safinamide 57 FDA Clears 57 DIFICID ™ 57 Receptor Agonist 57 REPEL CV 57 RAPAFLO 57 Plaque Psoriasis 57 EOquin TM 57 Centralized Procedure 57 faropenem medoxomil 57 IMiDs ® compound 57 FUSILEV ® 57 ORENCIA ® 57 forodesine 57 Patients Suffering 57 vinorelbine emulsion 57 Cardium Therapeutics TM 57 DexaSite 57 Vaccine Candidate 57 Nexavar sorafenib 57 Somatuline R Autogel R 57 Systemic Sclerosis 57 R rilonacept Injection 57 HCl Injection 57 Progenitor Cells 57 Receive Milestone Payment 57 RELISTOR ® 57 Pooled Analysis 57 Develop Novel 57 gastrointestinal stromal tumors 57 immunosuppressive compound 57 intravesical infusion therapy 57 Abstral ® 57 metastatic malignant 57 idiopathic thrombocytopenic purpura ITP 57 vidofludimus 57 Orapred ODT 57 FDA Approves 57 POTELLIGENT R Technology 57 LEVADEX TM 57 tramiprosate ALZHEMED TM 57 Voreloxin 57 Herceptin trastuzumab 57 IIa Clinical Trial 57 Commence Phase 57 Aeolus Pharmaceuticals Announces 57 Surgical Adhesive 57 IN PATIENTS WITH 57 PEG SN# 57 PRIALT 57 SFDA Approval 57 including eniluracil ADH 57 Disease Modifying 57 ketolide antibiotic 57 Demonstrates Positive 57 Ticagrelor 57 diabetic neuropathic pain 57 Regulatory Clearance 57 Roche Actemra 57 MabCampath 57 STELARA TM 57 Anti Tumor Activity 57 Edurant 57 highly purified pasteurized 57 nasal calcitonin product 57 taliglucerase alfa 57 serotonin norepinephrine reuptake inhibitor 57 IMiDs 57 tiapamil 57 rPA Anthrax Vaccine 57 XGEVA 57 Ozarelix 57 Daclizumab 57 Signaling Pathway 57 AMEVIVE 57 intranasal formulation 57 GED aPC 57 chronic immune thrombocytopenic 57 Phase III Pivotal 57 BioSante Pharmaceuticals Announces 57 ELACYT 57 Ranexa R 57 Augment ™ 57 BLA submission 57 Frozen Shoulder syndrome Adhesive 57 Cell Transplants 57 Campath alemtuzumab 57 sNDAs 57 opioid induced bowel dysfunction 57 Hepatocellular Carcinoma HCC 57 Phase IIa trials 57 Hypoactive Sexual Desire Disorder 57 tafamidis 57 eprodisate Fibrillex TM 57 Generic Versions 57 dihydrochloride Tablets 57 European Medicines Evaluation 57 Anastrozole 57 modified glutathione analog 57 OLpur TM H2H 57 Lupus Drug 57 ® lenalidomide 57 Allovectin 7 R 57 pregabalin Lyrica 57 Intravenous Human 57 FASLODEX 57 Hepatocellular Carcinoma 57 subcutaneous formulation 57 Vidaza R 57 Glybera R 57 eltrombopag 57 COLAZAL R 57 Vernakalant 57 Low Dose 57 volociximab 56 oncology indications 56 Ixabepilone 56 Phase 2a Study 56 unique alkylating agent 56 Junovan 56 neovascular age 56 PROMACTA CARES 56 AeroLEF TM 56 Metformin HCl 56 BAL# [002] 56 HFA MDI 56 Amigal 56 MOZOBIL 56 orBec 56 benign prostatic hypertrophy BPH 56 GALNS 56 Zelrix 56 Tesetaxel 56 PMA Supplement 56 RAPTIVA 56 #k Clearance 56 Breast Cancer Recurrence 56 Subpart E 56 Recurrent Glioblastoma 56 Acute Heart Failure 56 Receives FDA Clearance 56 IRX 2 56 Behcet uveitis 56 Filgrastim 56 temsirolimus 56 AZILECT R 56 Vicriviroc 56 XIAFLEX TM 56 Jevtana 56 candidate Zenvia 56 Lung Cancer Trial 56 Phase III Clinical Trials 56 Xenazine ® 56 efalizumab